C-4REZBiophytis
AI drug discovery, BIO101, longevity therapeutics
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-4REZ
C-4REZC-4REZAI drug discovery, BIO101, longevity therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Biophytis AI drug discovery, BIO101, longevity therapeutics
Biophytis is a biotechnology company developing transformative therapies impacting longevity. Its strategy includes a longevity research platform using multiple technologies accelerated by AI, plus BIO101 clinical programs in sarcopenia and obesity. The site describes BIO101 in sarcopenia as the most advanced clinical program in the world in sarcopenia.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Biophytis — Near-term readout · Bottom quartile. Derived deterministically from 6 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic